latest news releases from the newsroom
VIRxSYS and National Heart, Lung, and Blood Institute Sign Agreement
GAITHERSBURG, Md., Jan. 17, 2008 (PRIME NEWSWIRE) -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, today announced that they have signed a Co-operative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI), a branch of the National Institute of Health. The CRADA is a transition of the agreement with the Intronn Corp., which was acquired earlier this year by VIRxSYS.
Dime Community Bancshares, Inc.
Dime Community Bancshares Declares Quarterly Cash Dividend
BROOKLYN, N.Y., Jan. 17, 2008 (PRIME NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq:DCOM), the parent company of The Dime Savings Bank of Williamsburgh, announced that its Board of Directors has declared a quarterly cash dividend of $0.14 per share, payable on February 15, 2008, to all stockholders of record as of January 31, 2008. This dividend is the 43rd consecutive quarterly cash dividend paid by the Company.
New Discoveries Confirm and Enhance CombiMatrix's Microarray Test for Autism
MUKILTEO, Wash., Jan. 17, 2008 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced that today's publication in the American Journal of Human Genetics by Dr. Steve Scherer and colleagues further implicate genomic copy number variation (CNV) in the etiology of Autism Spectrum Disorder (ASD) elevating the importance of the CBMX ATScan(tm) 1.0 microarray test. The study reports the discovery of a chromosome 16p11.2 region in one percent of ASD patients identical to that described last week in the New England Journal of Medicine (Daly et al., NEJM), as well as numerous additional previously unreported ASD-risk genes. CBMX is proud to announce that, as a function of its unparalleled ability to rapidly enhance and clinically validate its genomic arrays, these new loci exist or are being added to the ATScan(tm) 1.0 establishing the CBMX platform as the most up-to-date and comprehensive diagnostic test of its kind for ASD. Moreover, as a function of CBMX's commitment to responsible and affordable diagnostics testing, the enhanced ATScan(tm) remains priced as the most affordable comparable test in the industry. We encourage physicians and patients to contact us at 949-753-0624 for more information.